Innovent Announces Primary Endpoint Met in the Phase 3 Clini

ROCKVILLIE, MD. and SUZHOU, China, Feb. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company

Related Keywords

China , Thailand , Minnesota , United States , Suzhou , Jiangsu , Xianqun , Qinghai , Shanghai , American , Chinese , Adimab Incyte , Alia Teprotumumab , Innovent Biologics , Eli Lilly , Innovent Biologics Inc , Group Of Oculoplastic , European Group On Grave Orbitopathy , American Thyroid Society , Chinese Ophthalmology Branch , European Thyroid Society , Linkedin , National Drug Administration , Clinical Development Of Innovent , European Thyroid Association , Chinese Medical Association , European Group On Grave , Chinese Endocrinology Branch , Group Of Thyroid Diseases , Academician Of The Chinese Academy Engineering , Md Anderson Cancer Center , Development Of Medicines , American Thyroid Association , Thyroid Eye Disease , Drug Evaluation , Chinese Academy , Ninth People , Hospital Affiliated , Shanghai Jiao Tong University School , Lei Qian , Vice President , Clinical Development , Chinese Clinical Diagnosis , Treatment Guidelines , European Group , European Thyroid , Olmsted Country , Trans Am Ophthalmol Soc , Grave Orbitopathy , Orbital Diseases , Thyroid Diseases , Chinese Medical , Chinese Guidelines , Thyroid Associated Ophthalmopathy , Chinese Journal , Consensus Statement , Eur Thyroid , Curr Opin , Retrieved June , Medscape Reference , Active Thyroid Eye Disease , Pract Res Clin Endocrinol , Thailand Business ,